A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions
Abstract Dasatinib, a second‐generation tyrosine kinase inhibitor, is approved for treating chronic myeloid and acute lymphoblastic leukemia. As a sensitive cytochrome P450 (CYP) 3A4 substrate and weak base with strong pH‐sensitive solubility, dasatinib is susceptible to enzyme‐mediated drug-drug in...
Furkejuvvon:
Váldodahkkit: | , , , , , , , |
---|---|
Materiálatiipa: | Girji |
Almmustuhtton: |
Wiley,
2024-07-01T00:00:00Z.
|
Fáttát: | |
Liŋkkat: | Connect to this object online. |
Fáddágilkorat: |
Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
Interneahtta
Connect to this object online.3rd Floor Main Library
Hildobáiki: |
A1234.567 |
---|---|
Njađus 1 | Oažžumis |